Overview

Safety of Lumiracoxib in Patients With Osteoarthritis

Status:
Completed
Trial end date:
2001-03-01
Target enrollment:
Participant gender:
Summary
This safety study evaluated the incidence of gastrointestinal adverse events and edema in patients with osteoarthritis treated with lumiracoxib and rofecoxib as comparator
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Diclofenac
Lumiracoxib
Rofecoxib